H.C. Wainwright downgraded 89bio (ETNB) to Neutral from Buy with a price target of $14.50, down from $32, after the company entered into a merger agreement to be acquired by Roche (RHHBY) for $14.50 per share in cash.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ETNB: